Study aim: The aim of this study was to evaluate the effectiveness of Dolatgravir diet and compare it with the standard diet used. Design: This study is a randomized, double-blind, placebo-controlled clinical trial. In order to eliminate Confounding by indication and Confounding by severity, patient and therapists will be blind to the type of treatment. Settings and conduct: Patients are divided into two groups of 50. In one group, the drug will be given at a dose of 50 mg for 7 days and the placebo will be administered with standard treatments in the other group. Patients and care provider are blinded. Participants/Inclusion and exclusion criteria: Inclusion: Aged between 18 to 80, Definitive diagnosis of covid-19, ≤8 days since illness onset, Having fever (≥ 37.8 ° C at any time), dry cough, shortness of breath or fatigue Involvement of 3 or more lobes of the pulmonary lobes or >O2Sat< 94% , Written consent of patients Exclusion: Severe hepatic impairment, Patients taking Phenytoin, Fosphenytoin, Oxcarbazepine, Phenobarbital, Primidone and St John's Wort, History of disease because of COVID-19, History of taking Covid-19 experimental drug, lactation, Requires intubation at admission, Sensitivity to Dolutegravir, Severe disability and Patient dissatisfaction with the study Intervention groups: Receive dulotegravir at a dose of 50 mg daily for 7 days + standard treatment regimen in the intervention group Receive placebo daily for 7 days + standard treatment regimen in the control group Main outcome variables: Clinical recovery after 14 days from the start of treatment, No need for intensive care and mechanical ventilation, Decrease the hospital admission time, Decrease the time to need nasal oxygen , Eradication of the virus from the nose and throat in RT-PCR test